Spots Global Cancer Trial Database for AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Official Title: A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma

Study ID: NCT00303862

Conditions

Clear Cell Renal Cell Carcinoma

Recurrent Renal Cell Cancer

Stage IV Renal Cell Cancer

Interventions

cediranib maleate

laboratory biomarker analysis

Study Description

Brief Summary: This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Detailed Description: PRIMARY OBJECTIVES: I. Determine the objective response rate in patients with refractory metastatic renal cell carcinoma treated with AZD2171. SECONDARY OBJECTIVES: I. Determine the safety and tolerability of AZD2171 in these patients. II. Determine the feasibility of performing standardized delayed contrast-enhancement-MRI correlative studies across different institutions and platforms with data-sharing capability in patients with metastatic renal cell cancer. III. Generate preliminary data regarding potential utility of pharmacogenomic and plasma/serum biomarkers of angiogenesis as predictive or prognostic markers for future investigations of AZD2171 and renal cell carcinoma. OUTLINE: This is a multicenter study. Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 6 weeks.